Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism

July 6, 2017 by Bob Yirka report
Images inside breast tumors after chemotherapy treatment, pointing out sites that promote cancer spreading. Credit: G.S. Karagiannis et al., Science Translational Medicine (2017)

(Medical Xpress)—A team of researchers working at the Albert Einstein College of Medicine in the U.S. has found evidence that suggests administering chemotherapy to breast cancer patients prior to surgery can put them at increased risk for metastasis. In their paper published in the journal Science Translational Medicine, the group describes how they followed the treatment of 20 cancer patients and tested them for structures in the blood that indicate a higher risk for cancer spreading and what they found.

One of the most common ways to treat breast cancer is to administer chemotherapy and then to perform surgery to remove the tumor. It is believed that in addition to reducing tumor size, the chemotherapy drugs reduce the chance of the cancer spreading to other parts of the body. But now, it appears that that the latter assumption may not only be wrong, but the opposite of what actually occurs.

In this new effort, the researchers began by noting that some recent studies have suggested that instead of reducing the spread of cancer, some chemotherapy drugs might actually be making it easier for cancer cells to migrate to other body parts. To find out if that might be true, the team measured levels of tumor microenvironment of metastasis (TMEMs) in 20 breast throughout their treatment. TMEMs are structures shown to be an indicator of metastasis. The researchers report that they found elevated levels of TMEMs in all of the patients that had received chemotherapy prior to having surgery.

The researchers also conducted research a breast cancer mouse model—they report that they found an increase in TMEM sites in mice that had received chemotherapy compared to those that did not.

The video will load shortly
Chemotherapies can induce changes within the breast tumor microenvironment that serve as sites to promote cancer spreading (indicated with arrow) Credit: G.S. Karagiannis et al., Science Translational Medicine (2017)

The researchers also found that one such chemotherapy drug in particular, paclitaxel, caused with TIE2 receptors to move to tumors, which resulted in TMEM formation. When they blocked the TIE2 with drugs, the number of TMEM sites in chemotherapy-treated mice did not increase.

The suggest that more research needs to be done to better ascertain if are causing cancers to spread and that in the meantime, some doctors may consider performing surgery first, then prescribing chemotherapy for patients.

The video will load shortly
Chemotherapies can induce changes within the breast tumor microenvironment that serve as sites to promote cancer spreading (indicated with arrow) Credit: G.S. Karagiannis et al., Science Translational Medicine (2017)

Explore further: Identification of a chemotherapy resistance factor in breast cancer patients

More information: Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism, Science Translational Medicine  05 Jul 2017: Vol. 9, Issue 397, eaan0026 , DOI: 10.1126/scitranslmed.aan0026 , http://stm.sciencemag.org/content/9/397/eaan0026

Abstract
Breast cancer cells disseminate through TIE2/MENACalc/MENAINV-dependent cancer cell intravasation sites, called tumor microenvironment of metastasis (TMEM), which are clinically validated as prognostic markers of metastasis in breast cancer patients. Using fixed tissue and intravital imaging of a PyMT murine model and patient-derived xenografts, we show that chemotherapy increases the density and activity of TMEM sites and Mena expression and promotes distant metastasis. Moreover, in the residual breast cancers of patients treated with neoadjuvant paclitaxel after doxorubicin plus cyclophosphamide, TMEM score and its mechanistically connected MENAINV isoform expression pattern were both increased, suggesting that chemotherapy, despite decreasing tumor size, increases the risk of metastatic dissemination. Chemotherapy-induced TMEM activity and cancer cell dissemination were reversed by either administration of the TIE2 inhibitor rebastinib or knockdown of the MENA gene. Our results indicate that TMEM score increases and MENA isoform expression pattern changes with chemotherapy and can be used in predicting prometastatic changes in response to chemotherapy. Furthermore, inhibitors of TMEM function may improve clinical benefits of chemotherapy in the neoadjuvant setting or in metastatic disease.

Related Stories

Identification of a chemotherapy resistance factor in breast cancer patients

May 19, 2016
Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 ...

Breast cancer prognosis of African-American patients may improve with chemotherapy before surgery

January 19, 2017
Administering chemotherapy to African-American breast cancer patients prior to surgery could improve their prognosis and survival rates from the disease, according to a new study.

Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy

February 22, 2017
Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

Chemotherapy effectiveness and initiation time after lung cancer surgery

January 5, 2017
A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new study published online ...

Presurgery chemotherapy may make advanced ovarian cancers responsive to immunotherapy

June 15, 2016
Bottom Line: Metastatic ovarian cancer patients treated with chemotherapy prior to surgery had altered immune cells in their tumors, and specific alterations identified suggest that immunotherapy given after chemotherapy ...

Which breast cancer patients need lymph nodes removed? Ultrasound narrows it down

February 2, 2015
Which breast cancer patients need to have underarm lymph nodes removed? Mayo Clinic-led research is narrowing it down. A new study finds that not all women with lymph node-positive breast cancer treated with chemotherapy ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.